Physicochemical Properties
| Molecular Formula | C99H167N19O30S |
| Molecular Weight | 2135.56 |
| CAS # | 250718-44-6 |
| Appearance | Typically exists as solids at room temperature |
| Synonyms | MALP-2 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | TLR2 TLR6 |
| ln Vitro | Macrophage-activating lipopeptide 2 (1 µg/mL, 24 h) can promote the expression of major endothelial adhesion molecules and leukocyte integrin receptors, thereby enhancing leukocyte endothelial adhesion[1]. Macrophage-activating lipopeptide 2 (1 µg/mL, 2 h) can promote the phosphorylation of protein kinase B and eNOS in endothelial MyEnd cells, thereby promoting NO release[1]. |
| ln Vivo | Macrophage-activating lipopeptide 2 (1 µg in 125 µL PBS; once a day; 10 days; intravenous injection) improves perfusion recovery and collateral growth in the hindlimbs of hypercholesterolemic Apoe-deficient mice subjected to experimental femoral artery ligation (FAL) [1]. |
| Cell Assay |
RT-PCR[1]. Cell Types: Endothelial MyEnd cells Tested Concentrations: 1 µg/mL Incubation Duration: 24 h Experimental Results: Caused a strong transient increase in mRNA levels of vascular cell adhesion molecule-1 (Vcam-1) after 1 hour, and also increased the levels of other major endothelial adhesion molecules, namely intercellular adhesion molecule-1 (Icam-1), E-selectin, and P-selectin, between 1-3 hours. Western Blot Analysis[1]. Cell Types: Endothelial MyEnd cells Tested Concentrations: 1 µg/mL Incubation Duration: 2 h Experimental Results: Promoted phosphorylation of protein kinase B and eNOS. |
| Animal Protocol |
Animal/Disease Models: 6-10 weeks old male C57BL/6 Hypercholesterolemic Apoe-deficient mice[1]. Doses: 1 µg in 125 µL PBS Route of Administration: Intravenous injection (i.v.); once daily; 10 days Experimental Results: Improved blood flow recovery and increased the growth of pre-existing collateral arteries in the upper and hind limbs, as well as the proliferation of endothelial cells and accumulation of peri collagenous macrophages in the collateral walls. |
| References |
[1]. The Lipopeptide MALP-2 Promotes Collateral Growth. Cells. 2020 Apr 16;9(4):997. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4683 mL | 2.3413 mL | 4.6826 mL | |
| 5 mM | 0.0937 mL | 0.4683 mL | 0.9365 mL | |
| 10 mM | 0.0468 mL | 0.2341 mL | 0.4683 mL |